Gensia Sicor Files Lawsuit Against American

Pharmaceutical Partners IRVINE, Calif. (PROTEXT) - Gensia Sicor Inc. (Nasdaq: GNSA)today announced that its wholly owned subsidiary, Gensia SicorPharmaceuticals, Inc., filed a lawsuit on April 23, 1999 in theSuperior Court of California for Orange County against AmericanPharmaceutical Partners ("APP") for breach of contract, breach ofthe implied covenant of good faith and fair dealing, unfaircompetition and declaratory relief. The suit alleges that APP hasbreached a distributorship agreement for certain Gensia SicorPharmaceuticals products by, among other things, acquiring andoperating a business which competes with Gensia SicorPharmaceuticals with respect to some of the same products. TheCompany is seeking damages in excess of $10 million in additionto a declaration that the Company has no obligation or liabilityto APP. Gensia Sicor Inc. is a vertically integrated pharmaceuticalcompany with proven expertise in the development, manufacturingand marketing of injectable pharmaceuticals and in the productionof specialty bulk drug substances utilizing synthesis orfermentation. The company is focused on the worldwide oncologyand injectable pharmaceutical markets. Gensia Sicor's commercialpharmaceutical businesses include Gensia Sicor Pharmaceuticals,Inc., a California-based manufacturer and marketer of multisourceinjectable drugs, SICOR-Societa Italiana Corticosteroidi S.p.A.and Diaspa S.p.A., both of Milan Italy, and Sicor de Mexico, S.A.de C.V. in Toluca, Mexico all which produce specialty bulk drugsubstances, and Lemery, S.A. de C.V. in Mexico City whichmanufactures injectable and oral finished multisource drugproducts. Gensia Sicor's company offices are located in Irvine,CA. This press release contains forward looking statements thatare subject to risks and uncertainties that could cause actualresults to differ materially from those set forth in the forwardlooking statements, including whether Gensia Sicor's suit will beupheld in a court of law, whether Gensia Sicor will receive anycompensatory damages and those matters set forth in the riskfactors section of Gensia Sicor's filings on Forms 10-K and 10-Qwith the Securities and Exchange Commission. These forwardlooking statements represent the Company's judgment as of thedate of this press release. The Company disclaims any intent orobligation to update these forward looking statements. For more information on the Company, visit Gensia Sicor's newweb site at www.gensiasicor.com. News releases are also availableat no charge through PR Newswire's News On-Call fax service. Fora menu of available news releases or to retrieve a specificrelease made by Gensia Sicor, call 800-758-5804, extension354050. Please retain these numbers for future reference. otsOriginal Text Service: Gensia Sicor Inc. Internet:http://www.newsaktuell.de Contact: Laurie W. Little of GensiaSicor Inc., 949-455-4879; or Carolyn Bass or Jim Byers, 415-296-7383, or Patricia Walsh or Mark Owen, 212-850-5600, all ofMorgen-Walke Associates, Inc. for Gensia Sicor Inc. Company NewsOn-Call: http://www.prnewswire.com/comp/354050.html or fax, 800-758-5804, ext. 354050 Web site: http://www.gensia.com Web site:http://www.gensiasicor.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT